Yes, CD25 can be targeted for therapeutic purposes. Monoclonal antibodies against CD25, such as daclizumab and basiliximab, have been developed to prevent organ transplant rejection by inhibiting IL-2 signaling. Additionally, targeting CD25 in cancer therapy aims to reduce the number of regulatory T cells, thereby enhancing the anti-tumor immune response.
